CL2025003547A1 - Antagonista del receptor de tipo 2 de melanocortina - Google Patents

Antagonista del receptor de tipo 2 de melanocortina

Info

Publication number
CL2025003547A1
CL2025003547A1 CL2025003547A CL2025003547A CL2025003547A1 CL 2025003547 A1 CL2025003547 A1 CL 2025003547A1 CL 2025003547 A CL2025003547 A CL 2025003547A CL 2025003547 A CL2025003547 A CL 2025003547A CL 2025003547 A1 CL2025003547 A1 CL 2025003547A1
Authority
CL
Chile
Prior art keywords
receptor antagonist
melanocortin
melanocortin type
type
receptor
Prior art date
Application number
CL2025003547A
Other languages
English (en)
Inventor
hirose Hideki
Matsumoto Shigemitsu
Noguchi Naoyoshi
Sasaki Satoshi
Ikoma Minoru
Fukushi Hideto
Hara Ryoma
Asano Kohei
Watanabe Koji
Ogino Masaki
Kasai Shizuo
Maekawa Tsuyoshi
Original Assignee
Scohia Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scohia Pharma Inc filed Critical Scohia Pharma Inc
Publication of CL2025003547A1 publication Critical patent/CL2025003547A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención describe, como una forma de realización de la invención, el compuesto heterocíclico (I) representado por la siguiente fórmula (I): en donde cada símbolo es como se define en la memoria descriptiva, o una de sus sales, que tiene una actividad antagonista contra el receptor de melanocortina 2 y útil para el tratamiento o profilaxis de enfermedades endocrinas y similares.
CL2025003547A 2023-05-16 2025-11-13 Antagonista del receptor de tipo 2 de melanocortina CL2025003547A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2023080580 2023-05-16

Publications (1)

Publication Number Publication Date
CL2025003547A1 true CL2025003547A1 (es) 2026-02-20

Family

ID=93519713

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2025003547A CL2025003547A1 (es) 2023-05-16 2025-11-13 Antagonista del receptor de tipo 2 de melanocortina

Country Status (13)

Country Link
EP (1) EP4714953A1 (es)
JP (1) JPWO2024237266A1 (es)
KR (1) KR20260009350A (es)
CN (1) CN120858097A (es)
AR (1) AR132690A1 (es)
AU (1) AU2024273541A1 (es)
CL (1) CL2025003547A1 (es)
CO (1) CO2025012255A2 (es)
IL (1) IL324502A (es)
JO (1) JOP20250278A1 (es)
MX (1) MX2025013542A (es)
TW (1) TW202509036A (es)
WO (1) WO2024237266A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200201119A1 (ru) * 2000-06-28 2003-06-26 Пфайзер Продактс Инк. Лиганды меланокортиновых рецепторов
JP7359783B2 (ja) 2018-06-05 2023-10-11 クリネティックス ファーマシューティカルズ，インク． メラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用
JP7657792B2 (ja) * 2019-11-07 2025-04-07 クリネティックス ファーマシューティカルズ，インク． メラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用
JP7734571B2 (ja) 2021-11-30 2025-09-05 株式会社日立製作所 プロセスモデル構築システム、プロセスモデル構築方法

Also Published As

Publication number Publication date
AR132690A1 (es) 2025-07-23
JPWO2024237266A1 (es) 2024-11-21
IL324502A (en) 2026-01-01
WO2024237266A1 (ja) 2024-11-21
KR20260009350A (ko) 2026-01-19
AU2024273541A1 (en) 2025-11-06
JOP20250278A1 (ar) 2025-11-09
CN120858097A (zh) 2025-10-28
MX2025013542A (es) 2025-12-01
TW202509036A (zh) 2025-03-01
EP4714953A1 (en) 2026-03-25
CO2025012255A2 (es) 2025-09-18

Similar Documents

Publication Publication Date Title
CO2020001879A2 (es) Compuesto heterocíclico y su uso
CL2021001973A1 (es) Compuesto heterocíclico y su uso.
MX2022016212A (es) Profármacos de tripamina.
MX2018009494A (es) Compuestos de piperidina sustituidos y su uso.
CL2018002505A1 (es) Inhibidores del envejecimiento proteico-proteico wdr5
MX2023000693A (es) Inhibidor de egfr.
CL2020001754A1 (es) Derivado de amino-fluoropiperidina como inhibidor de quinasa.
ECSP20035590A (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa
CU24411B1 (es) Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos
CR20150183A (es) Derivados de 5-fenoxi-3h-pirimidin-4-ona y su uso como inhibidores de la transcriptasa inversa del vih
CO2019012125A2 (es) Inhibidores ip6k
ECSP20035588A (es) Derivado de amino-metil piperidina como inhibidor de quinasa
CR20170092A (es) Compuestos y composiciones como inhibidores de quinasa raf
MX2018002889A (es) Compuesto de pirimidina fusionada o sal del mismo.
UY31781A (es) Derivados de iminopiridina y su uso
CO2025005865A2 (es) Compuesto heterocíclico
CU20200038A7 (es) Compuestos derivados de pirazolo-pirrolo-pirimidina-diona como inhibidores de p2x3
CL2025001563A1 (es) Compuesto heterocíclico y uso del mismo
CL2019002025A1 (es) Derivados de pirrolotriazina como inhibidor de cinasas.
CO2025012255A2 (es) Antagonista del receptor de tipo 2 de melanocortina
CO2019012270A2 (es) Compuesto heterocíclico
MX2017005271A (es) Compuestos de nargenicina y sus usos como agentes antibacterianos.
CO2025012357A2 (es) Compuestos heterocíclicos macrocíclicos y sus usos
CO2019012295A2 (es) Compuesto heterocíclico
UY36363A (es) Compuesto heterocíclico fusionado